Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022

Bharat, Chrianna; Chidwick, Kendal; Gisev, Natasa; Farrell, Michael; Ali, Robert; Degenhardt, Louisa

doi:10.1016/j.drugpo.2023.104255

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, in Australia, use of XR buprenorphine was as common as oral buprenorphine just over three years after it became available. (16) In Ontario, approximately 6% of people initiating opioid agonist treatment initiated XR buprenorphine just two years after approval. (17) In the US, limited availability at SUD treatment facilities that accept Medicaid may be a barrier to access.…”

Section: Discussionmentioning

confidence: 99%

Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022

Ross,

Rudolph,

Shover

2024

Preprint

View full text Add to dashboard Cite

Background and aimsExtended release buprenorphine injection (INJ-BUP) has been available in the United States since 2018. INJ-BUP has the potential to positively impact OUD treatment outcomes by providing additional treatment options and patient choice. We aimed to describe the availability and prescribing of INJ-BUP for Medicaid beneficiaries since its availability, nationwide and by state.MethodsTo assess availability, we measured the number of substance use disorder (SUD) facilities that offered INJ-BUP and accepted Medicaid insurance in 2018-2021 and calculated the percentage of all facilities offering medications of OUD. To assess prescribing, we measured the number of prescriptions for INJ-BUP paid by Medicaid 2018-2022 and calculated the percentage of all buprenorphine prescriptions paid by Medicaid. Data sources were publicly available.ResultsThe number of facilities that offered INJ-BUP and accepted Medicaid insurance increased from 360 (2.5% of all SUD facilities offering medication) in 2018 to 2,257 (13.3%) in 2021. The number of prescriptions for INJ-BUP paid by Medicaid increased from 4,322 (0.1% of all buprenorphine prescriptions) in 2018 to 186,861 (2.0%) in 2022. There was notable variability in the number of facilities and prescriptions by state.ConclusionsThere has been exponential increase in the number of INJ-BUP prescriptions but uptake is much less than observed in other countries in shorter time periods. Limited availability at SUD treatment facilities that accept Medicaid may be one barrier to access.

show abstract

Section: Discussionmentioning

confidence: 99%

Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022

Ross,

Rudolph,

Shover

2024

Preprint

View full text Add to dashboard Cite

show abstract

Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces

Boilard,

Wang,

Iacono

et al. 2024

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022

Ross,

Rudolph,

Shover

2024

Addiction

View full text Add to dashboard Cite

Background and aimsExtended release buprenorphine injection (INJ‐BUP) has been available in the United States since 2018. INJ‐BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options . As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ‐BUP. Uptake of INJ‐BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ‐BUP for Medicaid beneficiaries since 2018, nationwide and by state.MethodsWe analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ‐BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T‐MSIS SUD) Data Books. Data sources are publicly available.ResultsThe number of prescription fills for INJ‐BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.ConclusionsThe number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.

show abstract

Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022

Cited by 3 publications

References 27 publications

Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022

Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022

Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces

Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022

Contact Info

Product

Resources

About